New Clinical Trial: Stand tall with SHIELD – a blood test to improve lung cancer screening
April 13, 2022
Cancer screening is an effective way to detect cancer early when it can most easily be treated. Unfortunately, many people today are not being screened in line with recommendations.
Guardant Health is addressing this shortcoming by developing LUNAR-2, a blood test that seeks to increase screening rates and overcome the challenges of current methods, all from a simple blood draw.
To accomplish these objectives, Guardant Health is leveraging data from the tens of thousands of cancer patients it has already tested, as well as collaborating with multiple investigators at cancer centers around the world.
We at Guardant Health believe a simple blood test can improve lung cancer screening by overcoming barriers associated with current methods, such as low-dose CT scans, while still being effective and more accessible.
To be considered for the study, participants must meet the following criteria:
- Have an increased risk of lung cancer, including having at least a 20-pack/year smoking history and currently smoke or have quit within the past 15 years
- Be between 50 and 80 years old
- Are undergoing or intend to undergo a low-dose CT scan of the chest for lung cancer screening
- Are willing to consent to the investigational blood draw during index low-dose CT scan screening visit and before any invasive procedures or treatment for lung cancer diagnosis
- Are willing to consent to a 1-year, 2-year, and additional follow-up per protocol
- Additional criteria may apply
Talk to your doctor today for more information on the Guardant LUNAR-2 test and the SHIELD study. Or, reach out to Kristine Calabrese, Clinical Research Coordinator
at kcalabrese@starlingphysicians.com/(860) 224-6266 x6616
To learn more about other clinical trials and our new research department, click here.
